Calcitonin (porcine) |
Catalog No.GA21240
One-Click Copy Product Info
|
Calcitonin (porcine) is a 32-amino acid peptide hormone containing one disulfide bond, synthesized and secreted by the parafollicular cells of the porcine thyroid gland.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 12321-44-7
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Calcitonin (porcine) is a 32-amino acid peptide hormone containing one disulfide bond, synthesized and secreted by the parafollicular cells of the porcine thyroid gland. Calcitonin is a specific agonist of the calcitonin receptor (CTR). Calcitonin can be used for research and monitoring of Paget's disease of bone, osteoporosis (especially with bone pain), hypercalcemia, and medullary thyroid carcinoma[1-4].
In vitro, Calcitonin (10–100nM) was co-treated with 1,25-dihydroxyvitamin D₃ in porcine osteoclasts for 5–8 days. Calcitonin inhibited 1,25-dihydroxyvitamin D₃-stimulated osteoclast differentiation[5]. Calcitonin (0.01nM–1μM) was applied to LLC-PK1 cells for 10 minutes to 5 hours. Calcitonin dose-dependently elevated intracellular cAMP levels, suppressed LLC-PK1 cell proliferation, enhanced cellular Na⁺ uptake, and mildly reduced Ca²⁺ uptake[6].
In vivo, Calcitonin (0.25, 1.0MRC U/kg) was injected subcutaneously in pylorus-ligated Wistar rats before ligation and 6h after ligation. Calcitonin dose-dependently inhibited the accumulation of gastric juice, gastric acid, and pepsin induced by pyloric ligation[7]. Calcitonin (5 or 50MRC U/kg/day; divided into two subcutaneous injections) was administered subcutaneously to chronically ⁴⁵Ca-labeled 25-month-old female B7D2F1 mice for 25 consecutive days; Calcitonin (10 or 100MRC U/kg/day; divided into two subcutaneous injections) was given to chronically ⁴⁵Ca-labeled 10-month-old female Sprague-Dawley rats for 18 days. Calcitonin had no effect on ⁴⁵Ca excretion in 25-month-old mice; in 10-month-old rats, the 100U/kg/day group showed a transient decrease in ⁴⁵Ca excretion within approximately 10 days of dosing[8].
References:
[1] Kikumoto K, Katafuchi T, Minamino N. Specificity of porcine calcitonin receptor and calcitonin receptor-like receptor in the presence of receptor-activity-modifying proteins. Hypertens Res. 2003 Feb;26 Suppl:S15-23.
[2] Christmanson L, Westermark P, Betsholtz C. Islet amyloid polypeptide stimulates cyclic AMP accumulation via the porcine calcitonin receptor. Biochem Biophys Res Commun. 1994 Dec 15;205(2):1226-35.
[3] Buckle RM, Gamlen TR, Pullen IM. Vitamin D intoxication treated with porcine calcitonin. Br Med J. 1972 Jul 22;3(5820):205-7.
[4] Orme AL, Pento JT. Evidence of calcitonin-induced inhibition of calcitonin secretion in porcine thyroid slices. Proc Soc Exp Biol Med. 1976 Jan;151(1):110-2.
[5] Galvin RJ, Bryan P, Venugopalan M, et al. Calcitonin responsiveness and receptor expression in porcine and murine osteoclasts: a comparative study. Bone. 1998 Sep;23(3):233-40.
[6] Hamano K, Katafuchi T, Kikumoto K, et al. Calcitonin receptor-stimulating peptide-1 regulates ion transport and growth of renal epithelial cell line LLC-PK1. Biochem Biophys Res Commun. 2005 Apr 29;330(1):75-80.
[7] Bouley R, Lu HA, Nunes P, et al. Calcitonin has a vasopressin-like effect on aquaporin-2 trafficking and urinary concentration. J Am Soc Nephrol. 2011 Jan;22(1):59-72.
[8] Anderson GH, Draper HH. Effect of porcine calcitonin on bone resorption in adult rats and mice. Gerontologia. 1971;17(4):193-202.
| Cell experiment [1]: | |
Cell lines | LLC-PK1 cells (porcine renal proximal tubular epithelial cell line) |
Preparation Method | LLC-PK1 cells were maintained in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 100μg/mL penicillin, and 100U/mL streptomycin at 37°C, 5% CO₂. For cAMP measurement, cells were pretreated with DMEM/Hepes containing 0.5mM IBMX for 30min, then treated with Calcitonin at indicated concentrations for 30min. For proliferation assay, cells were treated with Calcitonin in DMEM with 10% FBS for 2h, then switched to medium containing ¹²⁵I-DU for an additional 5h. For ion uptake assays, cells were washed with calcium-free Hanks' solution or Hanks'-choline chloride solution and treated with Calcitonin. |
Reaction Conditions | 10-100nM; 10min-5h |
Applications | Calcitonin dose-dependently elevated intracellular cAMP levels in LLC-PK1 cells, inhibited LLC-PK1 cell proliferation, enhanced ²²Na⁺ uptake, and slightly reduced ⁴⁵Ca²⁺ uptake. Calcitonin-enhanced ²²Na⁺ uptake was abolished by 5-(N-ethyl-N-isopropyl) amiloride (EIPA) at 10nM, indicating that Calcitonin enhances ²²Na⁺ uptake via specific activation of NHE1. |
| Animal experiment [2]: | |
Animal models | 25-month-old female B7D2F1 mice and 10-month-old female Sprague-Dawley rats, both chronically labeled with ⁴⁵Ca |
Preparation Method | Mice received 4 intraperitoneal doses of 20μCi ⁴⁵CaCl₂ on alternate days, followed by a 7-week stock diet feeding to achieve deep bone labeling; rats received 4 doses of 100μCi ⁴⁵Ca on alternate days, with experiments starting 6 weeks later. After baseline ⁴⁸Ca excreta collection (48h), mice were divided into 3 groups receiving Calcitonin at 5 or 50MRC U/kg/day or vehicle (16% gelatin), subcutaneously in 2 divided doses 12h apart for 25 days; rats were divided into 3 groups receiving Calcitonin at 10 or 100MRC U/kg/day or vehicle, subcutaneously in 2 divided doses 12h apart for 18 days. ⁴⁵Ca excretion in combined excreta (mice) or separate urine/feces (rats) was monitored every 2–3 days; rat urine was additionally analyzed for Ca and P. |
Dosage form | Mouse: 5 or 50MRC U/kg/day; Rat:10 or 100 MRC U/kg/day; s.c.; twice daily; 25 days (mouse) or 18 days (rat) |
Applications | Calcitonin produced no consistent effect on ⁴⁵Ca excretion in 25-month-old mice over 25 days, indicating ineffectiveness in inhibiting bone resorption in aged mice. In 10-month-old rats, 100U/kg/day induced a transient depression in total ⁴⁵Ca excretion for ~10 days but was ineffective thereafter, while 10U/kg/day showed no discernible suppression; both doses increased urinary ⁴⁵Ca and total urinary Ca excretion in rats, without increasing urinary P excretion. |
References: | |
| Cas No. | 12321-44-7 | SDF | |
| Formula | C159H232N46O45S3 | M.Wt | 3604.07 |
| Solubility | Soluble in DMSO | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 277.5 μL | 1.3873 mL | 2.7746 mL |
| 5 mM | 55.5 μL | 277.5 μL | 554.9 μL |
| 10 mM | 27.7 μL | 138.7 μL | 277.5 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)